Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
PKG activity causes photoreceptor cell death in two retinitis pigmentosa models.
J. Neurochem. 108, 796-810 (2009)
Photoreceptor degeneration in retinitis pigmentosa is one of the leading causes of hereditary blindness in the developed world. Although causative genetic mutations have been elucidated in many cases, the underlying neuronal degeneration mechanisms are still unknown. Here, we show that activation of cGMP-dependent protein kinase (PKG) hallmarks photoreceptor degeneration in rd1 and rd2 human homologous mouse models. When induced in wild-type retinae, PKG activity was both necessary and sufficient to trigger cGMP-mediated photoreceptor cell death. Target-specific, pharmacological inhibition of PKG activity in both rd1 and rd2 retinae strongly reduced photoreceptor cell death in organotypic retinal explants. Likewise, inhibition of PKG in vivo, using three different application paradigms, resulted in robust photoreceptor protection in the rd1 retina. These findings suggest a pivotal role for PKG activity in cGMP-mediated photoreceptor degeneration mechanisms and highlight the importance of PKG as a novel target for the pharmacological intervention in RP.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
4.500
1.460
36
83
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
calcium; cGK; cGMP; nitric oxide; rd1 mouse; retina; dependent protein-kinase; vasodilator-stimulated phosphoprotein; inherited retinal degenerations; rod cgmp-phosphodiesterase; nucleotide-gated channels; d-cis-diltiazem; cyclic-gmp; mouse retina; rd mouse; guanosine-monophosphate
Sprache
englisch
Veröffentlichungsjahr
2009
HGF-Berichtsjahr
2009
ISSN (print) / ISBN
0022-3042
e-ISSN
1471-4159
Zeitschrift
Journal of Neurochemistry
Quellenangaben
Band: 108,
Heft: 3,
Seiten: 796-810
Verlag
Wiley
Begutachtungsstatus
Peer reviewed
Institut(e)
CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-505700-001
PubMed ID
19187097
Scopus ID
58149333254
Erfassungsdatum
2009-12-31